Quanterix Revises Merger Terms with Akoya Biosciences

Quanterix ( (QTRX) ) has shared an update.

On April 28, 2025, Quanterix Corporation announced an amended merger agreement with Akoya Biosciences, revising the terms of their previously announced merger. Under the new terms, Quanterix will issue fewer shares and pay $20 million in cash to Akoya shareholders, with Quanterix shareholders owning 84% of the combined entity. This strategic move aims to create value for shareholders and leverage combined resources to drive synergies and expedite profitability. The merger is expected to close in the second quarter of 2025, pending Akoya shareholder approval and other customary conditions.

Spark’s Take on QTRX Stock

According to Spark, TipRanks’ AI Analyst, QTRX is a Neutral.

Quanterix’s overall stock score is weighed down by its financial performance challenges, particularly in achieving profitability and positive cash flows. The bearish technical indicators and concerning valuation further impact the score negatively. However, the strategic acquisition of Akoya Biosciences and the positive growth outlook from the earnings call provide some optimism, preventing a lower score.

To see Spark’s full report on QTRX stock, click here.

More about Quanterix

Quanterix Corporation operates in the biotechnology industry, specializing in ultra-sensitive biomarker detection through its Simoa® technology. This technology is used for early biomarker detection in various fields such as neurology, oncology, immunology, cardiology, and infectious diseases. Akoya Biosciences, known as The Spatial Biology Company®, focuses on spatial phenotyping solutions, providing single-cell imaging technologies that help researchers understand disease progression and therapy responses.

YTD Price Performance: -46.28%

Average Trading Volume: 745,293

Technical Sentiment Signal: Buy

Current Market Cap: $224.2M

For detailed information about QTRX stock, go to TipRanks’ Stock Analysis page.